| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|---|---|---|---|---|---|---|---|
| Q4 2022 | 3 | $29.9M | GRAB, NU, PTCT | 13F-HR | 2/3/2023, 11:09 AM | |||
| Q3 2022 | 3 | $27M | GRAB, NU, PTCT | 13F-HR | 11/4/2022, 10:02 AM | |||
| Q2 2022 | 3 | $24.8M | GRAB, NU, PTCT | 13F-HR | 8/5/2022, 09:50 AM | |||
| Q1 2022 | 4 | $40.2M | +$17.7M | +$17.7M | GRAB, NU, PTCT, NEWT | 13F-HR | 5/6/2022, 08:23 AM | |
| Q4 2021 | 2 | $45.6M | +$45.2M | +$45.2M | GRAB, PTCT | 13F-HR | 2/4/2022, 08:44 AM | |
| Q3 2021 | 1 | $304K | $0 | -$27.9M | -$27.9M | PTCT | 13F-HR | 11/8/2021, 03:16 PM |
| Q2 2021 | 3 | $28.2M | +$238K | -$6M | -$5.77M | DCT, PTCT, NEWT | 13F-HR | 8/5/2021, 02:29 PM |
| Q1 2021 | 2 | $35.3M | $0 | -$74.5M | -$74.5M | DCT, PTCT | 13F-HR | 5/5/2021, 10:02 AM |
| Q4 2020 | 3 | $107M | +$102M | +$102M | DCT, SNY, PTCT | 13F-HR | 2/5/2021, 03:36 PM | |
| Q3 2020 | 3 | $5.12M | -$22.4M | -$22.4M | SNY, PHR, PTCT | 13F-HR | 10/30/2020, 01:41 PM | |
| Q2 2020 | 4 | $28.1M | +$4.44M | +$4.44M | SNY, PHR, PTCT, NEWT | 13F-HR | 8/11/2020, 11:03 AM | |
| Q1 2020 | 3 | $20.3M | +$3.41K | +$3.41K | SNY, PTCT, NEWT | 13F-HR | 4/30/2020, 09:33 AM | |
| Q4 2019 | 3 | $23.4M | +$4.6K | +$4.6K | SNY, PTCT, NEWT | 13F-HR | 2/14/2020, 10:00 AM | |
| Q3 2019 | 3 | $21.5M | +$3.5K | +$3.5K | SNY, NEWT, PTCT | 13F-HR | 11/6/2019, 10:58 AM | |
| Q2 2019 | 3 | $20.2M | -$8.5K | -$8.5K | SNY, NEWT, PTCT | 13F-HR | 8/7/2019, 10:25 AM | |
| Q1 2019 | 12 | $149M | +$10.6K | +$10.6K | MRK, SNY, BP, PFE, GSKXXXX | 13F-HR | 4/30/2019, 11:40 AM | |
| Q4 2018 | 12 | $138M | +$3.01K | +$3.01K | MRK, SNY, PFE, TTE, GSKXXXX | 13F-HR | 2/8/2019, 09:07 AM | |
| Q3 2018 | 13 | $151M | +$3.27K | -$862K | -$859K | MRK, SNY, TTE, BP, PFE | 13F-HR | 10/31/2018, 11:51 AM |
| Q2 2018 | 21 | $238M | +$1.42M | +$1.42M | MS, JPM, ADM, BP, MRK | 13F-HR | 7/27/2018, 10:17 AM | |
| Q1 2018 | 20 | $230M | +$224K | +$224K | MS, JPM, ADM, SNY, AZN | 13F-HR | 5/1/2018, 02:25 PM | |
| Q4 2017 | 18 | $230M | +$6.42K | +$6.42K | MS, JPM, SNY, ADM, AZN | 13F-HR | 1/26/2018, 01:08 PM | |
| Q3 2017 | 19 | $229M | MS, SNY, MRK, ADM, JPM | 13F-HR | 10/27/2017, 10:18 AM | |||
| Q2 2017 | 21 | $235M | +$4.74K | +$4.74K | MS, SNY, MRK, ADM, JPM | 13F-HR | 7/28/2017, 10:28 AM | |
| Q1 2017 | 20 | $232M | +$987 | +$987 | MS, ADM, SNY, MRK, JPM | 13F-HR | 5/4/2017, 08:30 AM | |
| Q4 2016 | 25 | $228M | +$1.02M | -$470 | +$1.02M | MS, ADM, SNY, MRK, JPM | 13F-HR | 2/14/2017, 01:48 PM |
| Q3 2016 | 24 | $221M | +$1.81M | -$16.2M | -$14.4M | ADM, MRK, GSKXXXX, SNY, AZN | 13F-HR | 11/14/2016, 04:49 PM |
| Q2 2016 | 25 | $231M | +$2.74M | -$470 | +$2.74M | ADM, SNY, GSKXXXX, MRK, AZN | 13F-HR | 8/12/2016, 11:28 AM |
| Q1 2016 | 34 | $367M | SNY, BAC, C, AAL, ADM | 13F-HR | 5/13/2016, 10:35 AM |